Elsevier

Brain Research

Volume 740, Issues 1–2, 18 November 1996, Pages 6-14
Brain Research

Cell surface APP751 forms complexes with protease nexin 2 ligands and is internalized via the low density lipoprotein receptor-related protein (LRP)

https://doi.org/10.1016/S0006-8993(96)00711-1Get rights and content

Abstract

The secreted isoforms of the amyloid precursor protein (APP) that contain the Kunitz domain are also known as protease nexin 2 (PN2). Normal proteolytic processing of transmembrane APP, which results in the majority of soluble PN2, cleaves within the Alzheimer's Aβ peptide, precluding Aβ formation. Recent data indicate that soluble PN2 is internalized by cells via the low density lipoprotein receptor-related protein (LRP), which binds multiple ligands including apolipoprotein E (apoE) [23]. However, soluble PN2 cannot contribute to amyloid accumulation, so we examined whether the unprocessed, transmembrane form of APP751 containing the intact Aβ sequence would form complexes with a PN2 ligand, EGF binding protein (EGFBP), and be internalized by LRP. We found that the addition of EGFBP to cells overexpressing APP751 induced the internalization of this amyloidogenic form of APP. The 39 kDa LRP receptor associated protein (RAP), an antagonist for LRP, blocked the internalization of APP751/PN2, suggesting a common LRP-mediated internalization pathway for both soluble and transmembrane APP751/PN2 after protease complex formation. Previous work has shown that internalization of transmembrane APP can lead to the formation of amyloidogenic carboxyl-terminal fragments and increased secretion of the Alzheimer's Aβ peptide. Our data suggest the protease ligands for PN2 may play an important role in altering APP processing pathways to favor amyloid formation, and that LRP may be a point at which the apoE and amyloid processing pathways intersect.

Reference (50)

  • Van NostrandW.E. et al.

    Protease nexin-II, a potent anti-chymotrypsin, shows identity to amyloid beta-protein precursor

    Nature

    (1989)
  • WillnowT.E. et al.

    Low density lipoprotein receptor-related protein and gp330 bind similar ligands, including plasminogen activator-inhibitor complexes and lactoferrin. an inhibitor of chylomicron remnant clearance

    J. Biol. Chem.

    (1992)
  • AschcomJ.D. et al.

    The human alpha 2-macroglobulin receptor: identification of a 420-kD cell surface glycoprotein specific for the activated conformation of alpha 2-macroglobulin

    J. Cell Biol.

    (1990)
  • BeisiegelU. et al.

    The LDL-receptor-related protein, LRP, is an apolipoprotein E-hinding protein

    Nature

    (1989)
  • CaiX.D. et al.

    Release of excess amyloid beta protein from a mutant amyloid beta protein precursor [see comments]

    Science

    (1993)
  • CheungT. et al.

    Characterization by radiosequencing of the carboxyl terminal derivatives produced from normal and mutant amyloid beta-protein precursors

    Amyloid

    (1994)
  • CitronM. et al.

    Excessive production of amyloid beta-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation

  • ColeG.M. et al.

    Evidence for lysosomal processing of amyloid beta-protein precursor in cultured cells

    Neutochem. Res.

    (1989)
  • CorderE.H. et al.

    Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families [see comments]

    Science

    (1993)
  • EschF.S. et al.

    Cleavage of amyloid beta peptide during constitutive processing of its precursor

    Science

    (1990)
  • EstusS. et al.

    Potentially amyloidogenic, carboxyl-terminal derivatives of the amyloid protein precursor [see comments]

    Science

    (1992)
  • GoldeT.E. et al.

    Processing of the amyloid protein precursor to potentially amyloidogenic derivatives [see comments]

    Science

    (1992)
  • HaassC. et al.

    Targeting of cell-surface beta-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments

    Nature

    (1992)
  • HaassC. et al.

    Amyloid beta-peptide is produced by cultured cells during normal metabolism [see comments]

    Nature

    (1992)
  • HerzJ. et al.

    Proteolytic processing of the 600 kD low density lipoprotein receptor-related protein (LRP) occurs in a trans-Golgi compartment

    EMBO J.

    (1990)
  • Cited by (105)

    • Role of LRP1 in the pathogenesis of Alzheimer's disease: Evidence from clinical and preclinical studies

      2017, Journal of Lipid Research
      Citation Excerpt :

      Accordingly, many interesting observations have been reported using cellular or animal models where LRP1 amount or function was biologically or genetically manipulated. Initial efforts were devoted to addressing the effects of LRP1 on APP trafficking and processing to Aβ by using cellular models, as it was known that LRP1 catabolizes tissue factor pathway inhibitor, and this protein shares the Kunitz protease inhibitor domain with the longer forms of APP (67–70). Blocking LRP1 function by RAP increased cell surface APP and reduced Aβ production in H4 cells stably expressing human APP (69).

    • The role of choroid plexus in IVIG-induced beta-amyloid clearance

      2014, Neuroscience
      Citation Excerpt :

      LRP1 serves as a receptor for these two proteins, and LRP1-mediated clearance of A2M and apoE contributes to a reduction in Aβ levels (Herz and Strickland, 2001). LRP1 may play a role in the BBB to transfer Aβ from the brain to the blood (Kounnas et al., 1995; Knauer et al., 1996; Goto and Tanzi, 2002; Moir and Tanzi, 2005; Yamada et al., 2009). Recently, LRP1 was identified in the CP.

    • Association of ApoE and LRP mRNA levels with dementia and AD neuropathology

      2012, Neurobiology of Aging
      Citation Excerpt :

      Later studies with APP transgenic mice carrying human ApoE isoforms show an isoform-specific effect on Aβ accumulation (murine apoE > ApoE4 > ApoE3 > ApoE2), and supported the hypothesis that ApoE is critical for the development of fibrillar, compact amyloid plaques. LRP has also been shown to interact directly with the extracellular domain of APP through its Kunitz-type serine protease inhibitor (KPI) domain and also indirectly with the cytoplasmic tail of APP through a common adapter protein FE65 (Kinoshita et al., 2001; Knauer et al., 1996; Kounnas et al., 1995; Pietrzik et al., 2004; Trommsdorff et al., 1998). Interestingly, an increase in Kunitz-type serine protease inhibitor (KPI) containing isoforms of APP protein levels has been reported in AD (Harrison et al., 1996; Moir et al., 1998; Preece et al., 2004).

    View all citing articles on Scopus
    View full text